FT
Flare TherapeuticsFlare Therapeutics is a clinical-stage biotech developing small-molecule drugs that target transcription factors, including a first-in-class ARON-targeting degrader for prostate cancer.
2 Pulse stories
ST
Scribe TherapeuticsClinical-stage biotech developing CRISPR-based gene-editing therapeutics using its proprietary CasX enzyme platform.
5 Pulse stories
Total Raised
$290M
Flare TherapeuticsScribe Therapeutics
Last ValuationNot disclosed
Biotech
Sector
Biotech
2021
Founded
2018
Cambridge, Massachusetts
HQ
Alameda, California
Private
Status
Public (SCTX)
Flare Therapeutics investors
Third Rock VenturesNextech InvestPfizer VenturesBoxer CapitalGordonMD Global InvestmentsInvusCasdin CapitalEli Lilly and Company
Scribe Therapeutics investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Flare Therapeutics and Scribe Therapeutics.